AustralianSuper Pty Ltd Buys New Position in Cencora, Inc. $COR

AustralianSuper Pty Ltd bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 83,804 shares of the company’s stock, valued at approximately $26,191,000.

Other institutional investors have also recently made changes to their positions in the company. GC Wealth Management RIA LLC bought a new stake in shares of Cencora during the 2nd quarter worth $332,000. Janney Montgomery Scott LLC raised its position in Cencora by 4.7% during the second quarter. Janney Montgomery Scott LLC now owns 45,984 shares of the company’s stock valued at $13,789,000 after purchasing an additional 2,058 shares in the last quarter. Capital Investment Advisors LLC lifted its stake in Cencora by 9.7% during the second quarter. Capital Investment Advisors LLC now owns 1,050 shares of the company’s stock worth $315,000 after purchasing an additional 93 shares during the last quarter. Cooper Financial Group purchased a new position in shares of Cencora in the 2nd quarter worth about $302,000. Finally, Impact Capital Partners LLC purchased a new position in shares of Cencora in the 2nd quarter worth about $206,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 20,316 shares of company stock valued at $7,151,265 in the last 90 days. Insiders own 0.38% of the company’s stock.

Cencora Stock Up 0.3%

Shares of NYSE COR opened at $351.49 on Friday. The firm’s fifty day moving average is $347.75 and its 200 day moving average is $323.44. Cencora, Inc. has a 52 week low of $237.71 and a 52 week high of $377.54. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The company has a market cap of $68.19 billion, a price-to-earnings ratio of 44.21, a PEG ratio of 1.67 and a beta of 0.66.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the firm earned $3.34 EPS. The company’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on COR shares. TD Cowen boosted their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Wells Fargo & Company lifted their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. UBS Group increased their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Barclays began coverage on shares of Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $393.08.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.